Prestige BioPharma Limited (KRX:950210)
South Korea flag South Korea · Delayed Price · Currency is KRW
9,560.00
+450.00 (4.94%)
Apr 16, 2026, 1:40 PM KST

Prestige BioPharma Revenue

Prestige BioPharma had revenue of 7.70B KRW in the quarter ending December 31, 2025, with 147.35% growth. This brings the company's revenue in the last twelve months to 19.02B, up 224.15% year-over-year. In the fiscal year ending June 30, 2025, Prestige BioPharma had annual revenue of 14.33B with 1,978.97% growth.

Revenue (ttm)
19.02B
Revenue Growth
+224.15%
P/S Ratio
5.76
Revenue / Employee
n/a
Employees
54
Market Cap
109.50B

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Jun 30, 202514.33B13.64B1,978.97%
Jun 30, 2024689.08M527.23M325.77%
Jun 30, 2023161.84M--
Jun 30, 2022---
Jun 30, 2021---
Jun 30, 2020 Pro Pro Pro
Jun 30, 2019 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
Macrogen195.27B
ORIENT BIO59.09B
Amicogen41.98B
CG Invites27.39B
GeneOne Life Science23.04B
iNtRON Biotechnology5.74B
IMB Dx5.33B
ENCell5.26B
Revenue Rankings